<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04639869</url>
  </required_header>
  <id_info>
    <org_study_id>NOV2019/01864</org_study_id>
    <nct_id>NCT04639869</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Feniramidol HCl 400 mg Film Tablet (Pharmactive, Turkey) Under Fed Conditions</brief_title>
  <acronym>PHENYRAMIDOL</acronym>
  <official_title>Open-label, Randomized, Single Dose, 4period, Replicated, Cross-over Trial to Assess the Bioequivalence of Feniramidol HCl 400 mg Film Tablet in Comparison With Cabral 400 mg Film Tablet in Healthy Male Subjects Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmactive Ilac Sanayi ve Tic A.S.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novagenix Bioanalytical Drug R&amp;D Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Farmagen Ar-Ge Biyot. Ltd. Sti</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharmactive Ilac Sanayi ve Tic A.S.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      OPEN-LABEL, RANDOMISED, SINGLE ORAL DOSE, FOUR-PERIOD, REPLICATED, CROSS-OVER TRIAL TO ASSESS&#xD;
      THE BIOEQUIVALENCE OF FENIRAMIDOL HCl 400 MG FILM TABLET (TEST DRUG) IN COMPARISON WITH&#xD;
      CABRAL 400 MG FILM TABLET (REFERENCE DRUG) IN HEALTHY MALE SUBJECTS UNDER FED CONDITIONS&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phenyramidol shows its muscle relaxant activity by interneuronal blockage without disrupting&#xD;
      neuromuscular function. Thus, it relieves muscle spasm, and breaks pain-spasm chain by&#xD;
      blocking polisynaptic reflexes in the brain and medulla spinalis. It does not affect&#xD;
      monosynaptic reflexes.&#xD;
&#xD;
      Phenyramidol has a very high analgesic effect than aspirin and close to codeine. It used in&#xD;
      the treatment of acute and chronic human musculoskeletal system pains as muscle relaxant and&#xD;
      analgesic.&#xD;
&#xD;
      Pharmacokinetics Phenyramidol reaches maximum plasma concentration in an hour (0.25-1) after&#xD;
      absorption from gastrointestinal tract. It is widely distributed in skeletal muscles and&#xD;
      involved in circulatory system very slowly.&#xD;
&#xD;
      Studies have shown that cytochrome P450 enzymes are effective in phenyramidol metabolism. It&#xD;
      is conjugated with glucuronic acid in the liver and it is excreted as glucuronide conjugates&#xD;
      from the urinary tract. The drug is eliminated from the bile and the bacterial glucuronidase&#xD;
      enzymes make the glucuronide conjugate of phenyramidol free. The drug enters enterohepatic&#xD;
      circulation and is excreted by faeces. Its elimination half-life is 1-2 hours.&#xD;
&#xD;
      Indications Phenyramidol is indicated in the symptomatic treatment of acute painful muscle&#xD;
      spasms associated with musculoskeletal system.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 26, 2019</start_date>
  <completion_date type="Actual">August 27, 2019</completion_date>
  <primary_completion_date type="Actual">July 26, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Full replicate cross-over bioequivalence study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0 to 10 hours post-dose</time_frame>
    <description>Cmax of phenyramydol will be obtained from plasma concentrations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt-last</measure>
    <time_frame>0 to 10 hours post-dose</time_frame>
    <description>AUC0-tlast of phenyramydol will be obtained from plasma concentrations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf</measure>
    <time_frame>0 to 10 hours post-dose</time_frame>
    <description>AUC0-inf of phenyramydol will be obtained from plasma concentrations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax</measure>
    <time_frame>0 to 10 hours post-dose</time_frame>
    <description>tmax of phenyramydol will be obtained from plasma concentrations</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Bioequivalence</condition>
  <arm_group>
    <arm_group_label>Phenyramydol then Cabral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants first receive Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cabral then Phenyramydol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants first receive Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S.in fed state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phenyramydol then Cabral Replicate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants first receive Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cabral then Phenyramydol Replicate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants first receive Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S.in fed state</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenyramydol HCl 400 mg Film Tablet</intervention_name>
    <description>Phenyramydol HCL 400 mg Film Tablet contains 400 mg phenyramydol manufactured by Pharmactive Ilac.San ve Tic A.S</description>
    <arm_group_label>Cabral then Phenyramydol</arm_group_label>
    <arm_group_label>Cabral then Phenyramydol Replicate</arm_group_label>
    <arm_group_label>Phenyramydol then Cabral</arm_group_label>
    <arm_group_label>Phenyramydol then Cabral Replicate</arm_group_label>
    <other_name>Test Phenyramydol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabral 400 mg Film Tablet</intervention_name>
    <description>Cabral 400 mg Film Tablet 400 mg phenyramydol manufactured by Recordati Ilac SAn ve Tic A.S.</description>
    <arm_group_label>Cabral then Phenyramydol</arm_group_label>
    <arm_group_label>Cabral then Phenyramydol Replicate</arm_group_label>
    <arm_group_label>Phenyramydol then Cabral</arm_group_label>
    <arm_group_label>Phenyramydol then Cabral Replicate</arm_group_label>
    <other_name>Reference Phenyramydol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Only volunteers fulfilling all of the following criteria should be enrolled in the present&#xD;
        trial:&#xD;
&#xD;
          1. Healthy Caucasian male subjects aged between 18 and 55 years,&#xD;
&#xD;
          2. Non smokers or smoking maximum 5 cigarettes a day, those who won't smoke or drink&#xD;
             coffee during each study period,&#xD;
&#xD;
          3. Negative alcohol breath test results,&#xD;
&#xD;
          4. Normal physical examination at screening visit,&#xD;
&#xD;
          5. Having the Body Mass Index ranged between 18.5-30 kg/m2 (see Appendix I) which is in&#xD;
             the desirable range according to the age,&#xD;
&#xD;
          6. Ability to communicate adequately with the investigator himself or his/her&#xD;
             representatives,&#xD;
&#xD;
          7. Ability and agreement to comply with the study requirements,&#xD;
&#xD;
          8. Normal blood pressure and heart rate measured under stabilised conditions at the&#xD;
             screening visit after at least 5 minutes of rest under supine position: SBP within 100&#xD;
             to 140 mmHg, DBP within 60 to 90 mmHg and HR within 50 to 90 bpm,&#xD;
&#xD;
          9. Normal/ acceptable 12-lead electrocardiographic results at least after 5 minutes of&#xD;
             rest,&#xD;
&#xD;
         10. Laboratory results within normal range or clinically non-significant (CBC, glucose,&#xD;
             urea, uric acid, creatinine, estimated GFR (eGFR), total bilirubin, sodium, potassium,&#xD;
             calcium, chloride, SGOT (AST), SGPT (ALT), GGT, alkaline phosphatase, total protein&#xD;
             and urinalysis), drug addiction scanning in urine results in negative (amphetamine,&#xD;
             barbiturate, benzodiazepine, cannabinoid, cocaine, opiate),&#xD;
&#xD;
         11. Understanding of the study and agreement to give a written informed consent according&#xD;
             to section 20.3.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Volunteers presenting any of the following exclusion criteria will not be included in the&#xD;
        trial:&#xD;
&#xD;
          1. Who have atopic constitution or asthma and/or known allergy for phenyramidol HCl or&#xD;
             any other ingredients of the products.&#xD;
&#xD;
          2. Any history or presence of clinical relevance of cardiovascular, neurological,&#xD;
             musculoskeletal, haematological, hepatic, gastrointestinal, renal, pulmonary,&#xD;
             endocrinological, metabolism or psychiatric disease, any type of porphyria.&#xD;
&#xD;
          3. Symptomatic or asymptomatic orthostatic hypotension at screening or before the first&#xD;
             drug administration defined by a decrease of SBP more than 20 mmHg or DBD more than 10&#xD;
             mmHg occurs between sitting/supine to standing position subject will be excluded (if&#xD;
             it deemed necessary by the investigator).&#xD;
&#xD;
          4. Presence or history of malabsorption or any gastrointestinal surgery except&#xD;
             appendectomy or except herniotomy.&#xD;
&#xD;
          5. Subjects who have given more than 400 mL blood within the last two months before the&#xD;
             first drug administration and subjects who have participated to any drug research&#xD;
             within the last two months before the first drug administration.&#xD;
&#xD;
          6. Subjects suspected to have a high probability of non-compliance to the study procedure&#xD;
             and/or completion of the study according to the investigator's judgement.&#xD;
&#xD;
          7. Subjects who used any of prescribed systemic or topical medication (including OTC&#xD;
             medication) within 2 weeks (or six elimination half lives of this medication,&#xD;
             whichever is longer) before the initiation of the study (except single doses of&#xD;
             analgesics which have no drug interaction with study product).&#xD;
&#xD;
          8. Use of any vitamins or herbal products within 7 days prior to the initial dose of the&#xD;
             study medication.&#xD;
&#xD;
          9. History of allergic response to heparin.&#xD;
&#xD;
         10. Subjects who have any chronic disease which might interfere with absorption,&#xD;
             distribution, metabolism or excretion of the drug.&#xD;
&#xD;
         11. Subjects who regular consumed of beverages or food containing methylxanthines (e.g.&#xD;
             coffee, tea, cola, caffeine, chocolate, sodas,) equivalent to more than 500 mg&#xD;
             methylxanthines per day.&#xD;
&#xD;
         12. Subjects who has taken any grapefruit or grapefruit juice during 7 days prior to drug&#xD;
             administration, during the study, or during the washout periods.&#xD;
&#xD;
         13. History of drug abuse.&#xD;
&#xD;
         14. History of alcohol abuse and/or regular use of more than 2 units of alcohol per day or&#xD;
             10 units per week and/or positive alcohol breath test results (Note: one unit of&#xD;
             alcohol equals 250 mL beer, 125 mL wine or 25 mL spirits).&#xD;
&#xD;
         15. Positive blood test for HBV, HCV and HIV.&#xD;
&#xD;
         16. Who have relationship to the investigator.&#xD;
&#xD;
         17. Who are not suitable to any of inclusion criteria.&#xD;
&#xD;
         18. History of difficulty of swallowing.&#xD;
&#xD;
         19. Intake of depot injectable solutions (including study medications) within 6 months&#xD;
             before start of the study.&#xD;
&#xD;
         20. Intake of enzyme-inducing, organotoxic or long half-life drugs within 4 weeks before&#xD;
             start of the study.&#xD;
&#xD;
         21. Special diet due to any reason, e.g. vegetarian.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muradiye Nacak, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Farmagen Ar-Ge Biyot. Ltd. Sti</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Taner Ezgi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Farmagen Ar-Ge Biyot. Ltd. Sti</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hakan Gürpınar, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Pharmactive İlaç San.ve Tic.A.S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novagenix Drug R&amp;D Center</name>
      <address>
        <city>Akyurt</city>
        <state>Ankara</state>
        <zip>06970</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 29, 2020</study_first_submitted>
  <study_first_submitted_qc>November 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2020</study_first_posted>
  <last_update_submitted>November 23, 2020</last_update_submitted>
  <last_update_submitted_qc>November 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phenyramidol</keyword>
  <keyword>Pharmactive Ilaç San.ve Tic. A.S</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 13, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT04639869/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 13, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT04639869/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

